Study identifies promising therapy to prevent relapses in rare neurological disease

An planetary survey led by Mayo Clinic researchers has identified interleukin-6 (IL-6) receptor blockers arsenic a promising enactment for preventing relapses successful myelin oligodendrocyte glycoprotein antibody-associated illness (MOGAD). MOGAD is simply a uncommon autoimmune neurological upset that tin origin imaginativeness loss, paralysis and different superior neurological complications.